Doxorubicin-anti-CEA monoclonal antibody conjugate

Drug Profile

Doxorubicin-anti-CEA monoclonal antibody conjugate

Alternative Names: DOX-CEA; Doxorubicin anti-CEA; Doxorubicin-anti-CEA antibody conjugate; Doxorubicin-anti-CEA conjugate

Latest Information Update: 14 Nov 2000

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunomedics
  • Class Monoclonal antibodies
  • Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Nov 2000 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 13 Nov 2000 Preclinical study results have been added to the pharmacokinetics and Cancer pharmacodynamics sections
  • 07 Nov 1997 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top